MX2013013752A - Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados. - Google Patents
Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados.Info
- Publication number
- MX2013013752A MX2013013752A MX2013013752A MX2013013752A MX2013013752A MX 2013013752 A MX2013013752 A MX 2013013752A MX 2013013752 A MX2013013752 A MX 2013013752A MX 2013013752 A MX2013013752 A MX 2013013752A MX 2013013752 A MX2013013752 A MX 2013013752A
- Authority
- MX
- Mexico
- Prior art keywords
- pirfenidone
- selected patients
- fibrotic therapy
- fibrotic
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención está relacionada a métodos para tratar fibrosos pulmonar con pirfenidona y/o otros agentes.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161489936P | 2011-05-25 | 2011-05-25 | |
US201161490057P | 2011-05-26 | 2011-05-26 | |
US201161523047P | 2011-08-12 | 2011-08-12 | |
US201161524961P | 2011-08-18 | 2011-08-18 | |
PCT/US2012/039538 WO2012162592A1 (en) | 2011-05-25 | 2012-05-25 | Pirfenidone and anti-fibrotic therapy in selected patients |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013013752A true MX2013013752A (es) | 2014-08-01 |
Family
ID=47217770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013013752A MX2013013752A (es) | 2011-05-25 | 2012-05-25 | Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20150164874A1 (es) |
EP (1) | EP2713732A4 (es) |
JP (1) | JP6170040B2 (es) |
KR (1) | KR20140022048A (es) |
AU (1) | AU2012258575B2 (es) |
CA (1) | CA2835438A1 (es) |
HK (1) | HK1197159A1 (es) |
IL (1) | IL229226A0 (es) |
MX (1) | MX2013013752A (es) |
SG (1) | SG195110A1 (es) |
WO (1) | WO2012162592A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101583737B1 (ko) | 2007-06-20 | 2016-01-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | 섬유증 저해제로서의 치환된 n-아릴 피리디논 |
KR20140011355A (ko) * | 2011-03-08 | 2014-01-28 | 오스펙스 파마슈티칼스, 인코포레이티드 | 치환된 n아릴 피리디논 |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
EP3027026A4 (en) * | 2013-07-31 | 2017-05-03 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
CN106459042B (zh) | 2014-04-02 | 2019-06-28 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
EP3194446B1 (en) * | 2014-09-18 | 2022-10-26 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
DK3050574T3 (da) * | 2015-01-28 | 2020-01-20 | Univ Bordeaux | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom |
US20180064662A1 (en) * | 2015-03-05 | 2018-03-08 | The General Hospital Corporation | Novel compositions and uses of metformin agents |
EP3595656A1 (en) * | 2017-03-13 | 2020-01-22 | Genfit | Pharmaceutical compositions for combination therapy |
JP2020531521A (ja) * | 2017-08-22 | 2020-11-05 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 抗アルファ(v)ベータ(6)抗体を含有する医薬組成物及び投薬計画 |
WO2020236615A1 (en) * | 2019-05-17 | 2020-11-26 | The Regents Of The University Of California | Mps modified peptides and use thereof |
CN112239507A (zh) * | 2019-07-17 | 2021-01-19 | 鸿运华宁(杭州)生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用 |
EP3821946A1 (en) * | 2019-11-12 | 2021-05-19 | Université de Strasbourg | Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases |
KR20220109439A (ko) | 2019-12-04 | 2022-08-04 | 이도르시아 파마슈티컬스 리미티드 | 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합 |
EP4117659A4 (en) * | 2020-03-13 | 2024-04-03 | Puretech Lyt 100 Inc | METHODS OF TREATING RESPIRATORY DISEASE WITH DEUTERATED PIRFENIDONE |
CN114617890A (zh) * | 2020-12-08 | 2022-06-14 | 四川夏派森医药科技有限公司 | DH404在治疗SARS-CoV-2感染中的应用 |
CN112640887B (zh) * | 2020-12-25 | 2022-05-13 | 武汉睿健医药科技有限公司 | 一种神经干细胞冻存液及其应用 |
WO2022266370A1 (en) * | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
CN114097807B (zh) * | 2021-11-25 | 2023-05-05 | 兰州大学 | 巴多索隆类化合物在抗农业病原真菌中的用途 |
WO2023192646A1 (en) * | 2022-03-31 | 2023-10-05 | Puretech Lyt 100, Inc. | Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001232340A1 (en) * | 2000-02-18 | 2001-08-27 | Kirin Beer Kabushiki Kaisha | Novel isoxazole and thiazole compounds and use thereof as drugs |
CN1307997C (zh) * | 2002-06-28 | 2007-04-04 | 图兰恩教育基金管理人 | 用于治疗肺纤维化的4-(4-甲基哌嗪-1-基甲基)-n-[4-甲基-3-(4-(吡啶-3-基)嘧啶-2-基氨基)苯基]-苯甲酰胺 |
US20070092488A1 (en) * | 2003-05-16 | 2007-04-26 | Intermune Inc. | Methods of treating idiopathic pulmonary fibrosis |
WO2005110478A2 (en) * | 2004-04-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating fibrotic disorders |
BRPI0709950A2 (pt) * | 2006-04-13 | 2011-08-02 | Actelion Pharmaceuticals Ltd | uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin |
MX349810B (es) * | 2006-09-08 | 2017-08-14 | Abbvie Bahamas Ltd | Proteinas de enlace de interleucina-13. |
KR101583737B1 (ko) * | 2007-06-20 | 2016-01-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | 섬유증 저해제로서의 치환된 n-아릴 피리디논 |
AU2010206543A1 (en) * | 2009-01-26 | 2011-07-07 | Intermune, Inc. | Methods for treating acute myocardial infarctions and associated disorders |
GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
-
2012
- 2012-05-25 CA CA2835438A patent/CA2835438A1/en not_active Abandoned
- 2012-05-25 JP JP2014512134A patent/JP6170040B2/ja not_active Expired - Fee Related
- 2012-05-25 KR KR1020137028921A patent/KR20140022048A/ko not_active Application Discontinuation
- 2012-05-25 US US14/373,276 patent/US20150164874A1/en not_active Abandoned
- 2012-05-25 WO PCT/US2012/039538 patent/WO2012162592A1/en active Application Filing
- 2012-05-25 MX MX2013013752A patent/MX2013013752A/es not_active Application Discontinuation
- 2012-05-25 SG SG2013086541A patent/SG195110A1/en unknown
- 2012-05-25 EP EP12788732.1A patent/EP2713732A4/en not_active Withdrawn
- 2012-05-25 AU AU2012258575A patent/AU2012258575B2/en not_active Ceased
-
2013
- 2013-11-04 IL IL229226A patent/IL229226A0/en unknown
-
2014
- 2014-10-06 HK HK14109929A patent/HK1197159A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
SG195110A1 (en) | 2013-12-30 |
CA2835438A1 (en) | 2012-11-29 |
JP6170040B2 (ja) | 2017-07-26 |
WO2012162592A1 (en) | 2012-11-29 |
NZ617415A (en) | 2017-07-28 |
AU2012258575B2 (en) | 2017-03-02 |
US20150164874A1 (en) | 2015-06-18 |
KR20140022048A (ko) | 2014-02-21 |
AU2012258575A1 (en) | 2013-11-21 |
HK1197159A1 (en) | 2015-01-09 |
EP2713732A4 (en) | 2014-12-03 |
JP2014518880A (ja) | 2014-08-07 |
IL229226A0 (en) | 2014-01-30 |
EP2713732A1 (en) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG195110A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
HK1209100A1 (en) | N-substituted benzamides and their use in the treatment of pain n- | |
MX2019008085A (es) | Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros. | |
IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
MX365835B (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
HK1180320A1 (en) | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd copd | |
HK1180322A1 (en) | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd copd | |
MX364220B (es) | Metodos de tratamientos de fibrosis. | |
ZA201402452B (en) | Novel pyrimethanil formulations and uses thereof in the treatment of crops | |
MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
GB2510524A (en) | Pulmonary hypertension | |
EP2710017A4 (en) | MACROCYCLIC THERAPEUTIC AGENTS AND METHODS OF TREATMENT | |
EP2744786A4 (en) | SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER | |
MX362111B (es) | Un metodo para mejorar la funcion hepatica. | |
HK1200731A1 (en) | Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy -[6-(4---- )--2--]- | |
MX351765B (es) | Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares. | |
LT2699545T (lt) | Nauji amino-pirolino dariniai ir jų naudojimas metabolinio sindromo prevencijai ir (arba) gydymui | |
PL2931716T3 (pl) | Pochodne pirydonu i ich zastosowanie w leczeniu gruźlicy | |
TN2013000404A1 (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease | |
HK1209073A1 (en) | Plod-2 stimulators and their use in the treatment of skin plod-2 | |
TN2015000236A1 (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis | |
UA70775U (ru) | Способ лечения менингококцемии у детей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD | Licence granted | ||
FA | Abandonment or withdrawal |